Proliferative Vitreoretinopathy (PVR) Therapeutics Development Pipeline Review, H1 2016 Featuring Novartis, Promedior & RXi Pharmaceuticals – Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H1 2016" report to their offering. This report provides comprehensive information on the therapeutic development for Proliferative Vitreoretinopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured n